Literature DB >> 16630524

Surgery for locally advanced disease.

Philippe E Spiess1, Dan Leibovici, Louis L Pisters.   

Abstract

Locally advanced prostate cancer is diagnosed in approximately one in four new cases of prostate cancer. The estimated disease-specific mortality rate resulting from monotherapy with either surgery or radiotherapy is a disappointing 75%. A multimodality treatment approach could offer more promising results. In addition, several key factors related to surgical treatment of locally advanced prostate cancer may optimize the oncologic results and minimize patient morbidity. In this report, we summarize some of the anatomic features and technical concepts associated with the surgical management of this disease and review recently published results of the outcomes of surgery and neoadjuvant or adjuvant chemohormonal therapy for locally advanced prostate cancer.

Entities:  

Mesh:

Year:  2006        PMID: 16630524     DOI: 10.1007/s11934-006-0023-z

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  49 in total

1.  Radical prostatectomy can provide a cure for well-selected clinical stage T3 prostate cancer.

Authors:  H Van Poppel; H Goethuys; P Callewaert; L Vanuytsel; W Van de Voorde; L Baert
Journal:  Eur Urol       Date:  2000-10       Impact factor: 20.096

2.  The prostatic capsule: does it exist? Its importance in the staging and treatment of prostatic carcinoma.

Authors:  A G Ayala; J Y Ro; R Babaian; P Troncoso; D J Grignon
Journal:  Am J Surg Pathol       Date:  1989-01       Impact factor: 6.394

3.  Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.

Authors:  John F Ward; Jeffrey M Slezak; Michael L Blute; Erik J Bergstralh; Horst Zincke
Journal:  BJU Int       Date:  2005-04       Impact factor: 5.588

Review 4.  Management of locally advanced prostate cancer. 1. Staging, natural history, and results of radical surgery.

Authors:  D van den Ouden; F H Schröder
Journal:  World J Urol       Date:  2000-06       Impact factor: 4.226

5.  [Radical prostatectomy as monotherapy for locally advanced prostate cancer (T3a): 12 years follow-up].

Authors:  Santiago Isorna Martínez de la Riva; José Belón López-Tomasety; Reinaldo Marrero Domínguez; Enrique Alvarez Cruz; Paloma Santamaría Blanco
Journal:  Arch Esp Urol       Date:  2004-09       Impact factor: 0.436

6.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

Authors:  Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

7.  High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer.

Authors:  M L Cher; K Shinohara; S Breslin; J Vapnek; P R Carroll
Journal:  Br J Urol       Date:  1995-06

8.  Transrectal ultrasound versus magnetic resonance imaging for detection of rectal wall invasion by prostate cancer.

Authors:  Dan Leibovici; Ashish M Kamat; Kim A Do; Curtis A Pettaway; Chaan S Ng; Robert B Evans; Miguel Rodriguez-Bigas; John Skibber; Xuemei Wang; Louis L Pisters
Journal:  Prostate       Date:  2005-01-01       Impact factor: 4.104

9.  Long-term results of adjuvant hormonal therapy plus radiotherapy following radical prostatectomy for patients with pT3N0 or pT3N1 prostate cancer.

Authors:  Hideaki Miyake; Iori Sakai; Ken-ichi Harada; Isao Hara; Hiroshi Eto
Journal:  Int J Urol       Date:  2004-06       Impact factor: 3.369

10.  Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity.

Authors:  S E Lerner; M L Blute; H Zincke
Journal:  J Urol       Date:  1995-10       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.